Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchEnsovibepEnsovibep (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Ensovibep for COVID-19
2 studies from 81 scientists
Statistically significant lower risk for hospitalization.
One study shows statistically significant improvement.
COVID-19 Ensovibep studies. Apr 2024. c19early.org
0 0.5 1 1.5+ All studies 46% Mortality 46% Hospitalization 87% RCTs 46% RCT mortality 46% Early 89% Late 17% Favorsensovibep Favorscontrol
Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies. Submit updates/corrections.
Apr 11
Covid Analysis Ensovibep for COVID-19: real-time meta analysis of 2 studies
Statistically significant lower risk is seen for hospitalization. One study shows statistically significant improvement. Meta analysis using the most serious outcome reported shows 46% [-173‑89%] lower risk, without reaching st..
Aug 9
2022
Barkauskas et al., Annals of Internal Medicine, doi:10.7326/M22-1503 Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
17% lower mortality (p=0.46), 6% improved recovery (p=0.55), and 7% higher hospital discharge (p=0.46). RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg.
Jan 10
2022
Novartis, Press Release Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
89% lower mortality (p=0.06), 87% lower hospitalization (p=0.01), and 78% fewer combined hospitalization/ER visits (p=0.02). EMPATHY Part A RCT with 407 patients, 301 treated with ensovibep, showing statistically significant viral load reduction (details not provided), and lower mortality and hospitalization. For discussion see [twitter.com].
Nov 16
2021
Molecular Partners, Press Release Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19
News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized.
Feb 3
2021
Rothenberger et al., bioRxiv, doi:10.1101/2021.02.03.429164 Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
In Silico, In Vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit